@article{acf26a75985647d69422bd74021b4bd0,
title = "Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia",
abstract = "Azacitidine is the standard of care for higher-risk myelodysplastic syndromes (MDS). We evaluated factors affecting the outcome of azacitidine treatment in 196 'real-world' patients, retrospectively collected by two Italian cooperative groups.",
keywords = "AML, MDS, azacitidine, AML, MDS, azacitidine",
author = "Voso, {Maria Teresa} and Pasquale Niscola and Alfonso Piciocchi and Luana Fianchi and Luca Maurillo and Pellegrino Musto and Livio Pagano and Giovanna Mansueto and Mansueto, {Giovanna Rosaria} and Marianna Criscuolo and Aloe-Spiriti, {Maria Antonietta} and Francesco Buccisano and Adriano Venditti and Andrea Tendas and Piccioni, {Anna Lina} and {Zini Tanzi}, Gina and Roberto Latagliata and Nunzio Filardi and Filardi, {Antonia Natalina} and Alberto Fragasso and Susanna Fenu and Massimo Breccia and Marco Breccia",
year = "2015",
doi = "10.1111/ejh.12595",
language = "English",
volume = "2015",
pages = "N/A--N/A",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "John Wiley and Sons Inc.",
}